Duoling (DUOL) Names John Lilly to Board

Duolingo, Inc. (Nasdaq: DUOL), the world's leading mobile language learning platform, announced today that it has named John Lilly as a new independent board director and member of the Compensation and Leadership Committee.

Mr. Lilly has had a prominent career, spanning over 25 years, during which he’s held various leadership roles in consumer and enterprise technology. He is a venture partner at Greylock Partners, where he led investments in Instagram, Dropbox, Tumblr, Figma and Quip, among others. John is the former CEO and Board Member of Mozilla, the organization behind Firefox, the open-source Web browser. He also co-founded Reactivity, an internet security infrastructure company acquired by Cisco in 2007, where he served as founding CEO and later CTO. Earlier in his career, John held positions on the executive team at Trilogy Software and as a Senior Scientist in Apple’s research labs.

He currently serves on the Board of Directors of Figma, Caffeine, Clockwise, Code for America, Voting Works and Nuro. He previously served on the Boards of Directors of TripIt, CenterRun, Mozilla, and Reactivity.

“Duolingo is firmly committed to providing universal access to the world’s best education,” said Luis von Ahn, Co-Founder and CEO of Duolingo. “John’s deep digital expertise, leadership roles, and proven track record of driving transformational initiatives for consumer technology companies will be a valuable addition to our Board of Directors.”

John holds a BS in Computer Systems Engineering and an MS in Computer Science with a focus on Human-Computer Interaction, both from Stanford University. He is currently a Lecturer at Stanford’s Graduate School of Business and was previously a Consulting Assistant Professor at Stanford’s d.school.

He is a co-inventor on seven United States patents.

You May Also Be Interested In

• Serve Robotics names Andreas Lieber to its board of directors
• Calidi Biotherapeutics adds biopharma veteran Corsee Sanders to board
• Illumina adds Eli Lilly's chief scientific officer to its board